Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

Overview of attention for article published in The Lancet, September 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 58 news outlets
blogs: 6 blogs
policy: 1 policy source
twitter: 1174 X users
patent: 1 patent

facebook: 12 Facebook pages
reddit: 3 Redditors
guideline: 1 clinical guideline source
bluesky: 5 Bluesky users

Readers on

mendeley: 572 Mendeley

So far, Altmetric has seen 5 Bluesky posts from 5 Bluesky users, with an upper bound of 207,506 followers.

RP @boghuma.bsky.social: 5/ DTaP: Combined vaccine replaced three monovalent injections equal safety, better adherence. pubmed.ncbi.nlm.nih.gov/33483215/ HPV-9 vaccine trial: >15 000 participants in trials; safety identical to earlier versions. www.thel…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity, including 1 additional Bluesky posts.